


Dapagliflozin impurity

Cat. No.:	HY-128723		
CAS No.:	960404-86-8		
Molecular Formula:	C ₂₁ H ₂₅ ClO ₇		
Molecular Weight:	424.87		
Target:	SGLT		
Pathway:	Membrane Transporter/Ion Channel		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 25 mg/mL (58.84 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.3537 mL	11.7683 mL	23.5366 mL
5 mM	0.4707 mL	2.3537 mL	4.7073 mL
10 mM	0.2354 mL	1.1768 mL	2.3537 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 1.43 mg/mL (3.37 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 1.43 mg/mL (3.37 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Dapagliflozin impurity is an enantiomer of Dapagliflozin which is a sodium-glucose transporter 2 inhibitor^[1].

REFERENCES

- [1]. Kasichayanula S, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. *Diabetes Obes Metab.* 2011 Jan;13(1):47-54.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA